Abstract:Background Peripheral T-cell lymphoma (PTCL) is a highly heterogenous hematological malignancy with poor outcome and prognosis, many patients experience recurrence. Histone deacetylase inhibitors (HDACis) have been proven to improve the prognosis of patients with relapsed/refractory (R/R) PTCL. Tucidinostat is a novel HDACi approved for treating R/R PTCL, however，clinical data is needed to determine the effectiveness of tucidinostat maintenance therapy in PTCL. Objective To retrospectively evaluate the efficacy and safety of tucidinostat maintenance in PTCL patients who achieved objective response after first-line therapy. Methods This is a retrospective, single-center, case-control study. We reviewed 473 newly diagnosed PTCL patients in the First Affiliated Hospital, Zhejiang University School of Medicine(Zhejiang, China) from January 2014 to December 2021. After excluding patients with insufficient clinical data, other concurrent tumor, natural killer/T-cell lymphoma, mycosis fungoides, or sequential transplantation, there were 32 PTCL patients who achieved objective response after first-line therapy received tucidinostat maintenance therapy. Patients who achieved objective response without maintenance therapy served as a candidate control pool. The two groups of patients were subjected to 1:1 propensity score matching (matching tolerance = 0.02), according to whether the international prognostic index (IPI) was ≥3, pathological subtype, whether the given patient was older than 65 years, and gender; 25 pairs (n = 50) were matched. The primary endpoints of this study were progress-free survival (PFS), overall survival (OS), and adverse events (AEs). The baseline clinical characteristics were compared using t-test for continuous variables, and chi-square or Fisher's exact test for categorical variables. Survival outcomes were assessed with Kaplan-Meier method. P < 0.05 was considered significant. The SPSS v25.0 software was used for statistical analysis. Results Among the patients in the tucidinostat maintenance (n = 25) and control (n = 25) groups, the median ages were 64 (30-90) and 63 (18-79) years old, respectively; the male ratios were 64.0% (16/25) and 68.0% (17/25), respectively; the proportions of patients ≥65 years were 44.0% (11/25) and 40.0% (10/25), respectively; the proportions of patients with IPI ≥3 were 52.0% (13/25) and 44.0% (11/25), respectively; and the proportions of patients with PIT ≥2 were 48.0% (12/25) and 44.0% (11/25), respectively (all P >0.05), suggesting a balanced distribution of baseline clinical characteristics in the 2 groups (Table 1). The complete response rates of the case and control groups were 72.0% (18/25) and 56.0% (14/25), respectively (P >0.05); the median duration of follow-up was 27.4 (6.7-96.0) and 22.2 (4.3-99.6) months, respectively; the median PFS was 54.0 and 12.3 months, respectively; the 2-year PFS was 67.9% and 25.3%, respectively (P < 0.01, Figure 1A); the median OS was unreached and 37.3 months, respectively; and the 2-year survival rate was 100% and 54.6%, respectively (P < 0.01, Figure 1B). No significant differences in PFS were observed between the 25 patients after matching and all of the 32 patients on tucidinostat maintenance (P = 0.878), indicating that there was no significant selection bias and the case group could represent the overall population. The total sample of 32 patients received 20 or 30 mg tucidinostat (both P.O., twice weekly) according to their physical status, age, and tolerance. Among them, 59.4% (19/32) took 20 mg (2 cases had dose reduction to 10-15 mg due to AEs) and 40.6% (13/32) took 30 mg (2 cases had dose reduction to 20 mg due to AEs), with median duration of 12.9 (2.4-86.4) months. The most common grade 3-4 AEs were neutropenia (28.1%), thrombocytopenia (15.6%), and anemia (12.5%), which mostly occurred within 6 weeks of initial administration and were relieved after symptomatic treatment . Conclusion Our retrospective case-control data preliminarily shows that tucidinostat maintenance is effective and has manageable safety for PTCL patients who acheived objective responses after first-line therapy, and increases their PFS and OS. However, a larger-sample, prospective, multicenter cohort study is needed to further determine the optimal dosage of tucidinostat maintenance and verify its therapeutic efficacy and safety. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Supplementary Table S2 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Table S3 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Table S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Table S6 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Table S5 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Method 1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Supplementary Figure S2 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study

Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas

Tucidinostat Maintenance after Achieving Objective Response to First-Line Therapy in Peripheral T-Cell Lymphoma: A Single-Center Retrospective Case-Control Study

ENHANCER OF ZESTE HOMOLOG 2 (EZH2) INHIBITOR SHR2554 IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL): UPDATED OUTCOMES FROM THE FIRST‐IN‐HUMAN PHASE 1 STUDY

Supplementary Table 2 from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed And/or Refractory Hematologic Malignancies

Supplementary Data and Figures from Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: an Open-label, Dose Escalation and Expansion Study

15P Preliminary Results of Histone Deacetylase Inhibitor Tucidinostat Combined with PD-1 Inhibitor Sintilimab in Non-Small Cell Lung Cancer Failed to Standard Therapies